BIOCOM for BIOCOM
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Submitted comments on the Cures 2.0 draft legislation Advocated for antimicrobial resistance legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
Taxation/Internal Revenue Code TAX
Expressed concerns with tax provisions in the FY2022 reconciliation bill, including raising the corporate tax rate and limiting the orphan drug tax credit
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
Copyright/Patent/Trademark CPT
Expressed importance of intellectual property protections for the life science industry. Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURE FABREGA CLARK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.